GFAP – Medxy AI

Serum Glial Fibrillary Acidic Protein Dynamics in Multiple Sclerosis: Biomarker Insights into Disease Progression and Therapeutic Response

By MedXY 08/04/2026

Serum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.

Critical Care news Pediatrics

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO

By MedXY 03/02/2026

This multi-center study demonstrates that serial monitoring of plasma GFAP and NfL biomarkers can detect acute brain injury in pediatric ECMO patients before imaging diagnosis, significantly correlating with long-term survival and functional outcomes.

Neurology news Radiology

Midlife Plasma GFAP as a Long-Term Sentinel for Cerebral Small Vessel Disease: A Decadal Prospective Study

By MedXY 01/06/2026

Elevated plasma glial fibrillary acidic protein (GFAP) in middle age independently predicts the progression of cerebral small vessel disease MRI markers nearly a decade later, suggesting its potential as an early-stage prognostic biomarker for neurovascular decline.